Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 5 institutions in 3 countries.
Luciana C LimaDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.ORCID 0000-0002-6560-4660
Rodolfo F MarquesDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.ORCID 0000-0003-4402-9131
Alba Marina GimenezDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
Katia S FrançosoDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
Eduardo AliprandiniUnit of Malaria Infection & Immunity, Institut Pasteur, 75015 Paris, France.
Tarsila M CamargoDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.
Anna Caroline C AguiarSão Carlos Institute of Physics, University of São Paulo, São Carlos, SP 13563-120, Brazil.
Dhelio B PereiraCentro de Pesquisas em Medicina Tropical, Porto Velho, RO 76812-329, Brazil.ORCID 0000-0002-7761-5498
Laurent ReniaSingapore Immunology Network, Biopolis, Agency for Science Technology and Research, Singapore 138632, Singapore.ORCID 0000-0003-0349-1557
Rogerio AminoUnit of Malaria Infection & Immunity, Institut Pasteur, 75015 Paris, France.
Irene S SoaresDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP 05508-000, Brazil.ORCID 0000-0002-3336-6856
Universidade de São Paulo · BRInstitut Pasteur · FRAgency for Science, Technology and Research · SGFaculdade de Medicina do ABC · BRUniversidade Federal de São Carlos · BR
Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo 2012/13032-5, 2014/18102-7, 2018/17364-9Institut Pasteur- Paris, and the French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" ANR-10-LABX-62-IBEIDNational Institute for Vaccine Development and Technology/Conselho Nacional de Desenvolvimento Científico e Tecnológico 465293/2014-0
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Multistage Formulation Based on Full-Length CSP and AMA-1 Ectodomain of · full record | OpenQuestion